Amgen Quarterly Income Statement
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amgen revenue and earnings
In the quarter ended Jun 30, 2026, Amgen generated $10.05 billion in revenue, up 9.5% from the same quarter a year earlier. Net income was $2.38 billion (+65.9% year over year), for a net margin of 23.6% versus a median of 21.1% in the prior 5 quarters. Gross margin was 72.0% (up from 67.2%) and operating margin 35.0%.
Diluted earnings per share came in at $4.37, up from $2.65.
Summary generated from market data by MetaCap's automated system. Methodology
Amgen income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.05B | 8.62B | 9.87B | 9.56B | 9.18B | 8.15B | 9.09B | 8.50B | 8.39B | 7.45B | 8.20B | 6.90B |
| Revenue growth (YoY) | +9.53% | +5.76% | +8.58% | +12.40% | +9.43% | +9.43% | +10.86% | +23.18% | +20.07% | +21.98% | +19.84% | +3.77% |
| Cost of Revenue | 2.81B | 2.74B | 2.98B | 3.08B | 3.01B | 2.97B | 3.11B | 3.31B | 3.24B | 3.20B | 3.11B | 1.81B |
| Gross Profit | 7.24B | 5.87B | 6.89B | 6.47B | 6.17B | 5.18B | 5.97B | 5.19B | 5.15B | 4.25B | 5.08B | 5.10B |
| Operating Expenses | 3.73B | 3.21B | 4.17B | 3.95B | 3.51B | 4.00B | 3.66B | 3.15B | 3.24B | 3.26B | 3.81B | 3.08B |
| Research & Development | 1.87B | 1.72B | 2.14B | 1.90B | 1.74B | 1.49B | 1.72B | 1.45B | 1.45B | 1.34B | 1.53B | 1.08B |
| Selling, General & Admin | 1.75B | 1.60B | 1.95B | 1.72B | 1.69B | 1.69B | 1.88B | 1.63B | 1.78B | 1.81B | 2.27B | 1.35B |
| Operating Income | 3.51B | 2.67B | 2.72B | 2.53B | 2.66B | 1.18B | 2.31B | 2.05B | 1.91B | 991.00M | 1.27B | 2.02B |
| Interest Expense | 673.00M | 657.00M | 653.00M | 685.00M | 694.00M | 723.00M | 747.00M | 776.00M | 808.00M | 824.00M | 821.00M | 759.00M |
| Other Income (Expense) | -73.00M | 75.00M | -553.00M | 2.08B | -394.00M | 1.52B | -782.00M | 1.83B | -307.00M | -235.00M | 402.00M | 685.00M |
| Pretax Income | 2.77B | 2.08B | — | 3.92B | 1.57B | 1.97B | 782.00M | 3.10B | 794.00M | -68.00M | 852.00M | 1.95B |
| Income Tax | 393.00M | 265.00M | 181.00M | 705.00M | 136.00M | 243.00M | 155.00M | 271.00M | 48.00M | 45.00M | 85.00M | 217.00M |
| Net Income | 2.38B | 1.82B | 1.33B | 3.22B | 1.43B | 1.73B | 627.00M | 2.83B | 746.00M | -113.00M | 767.00M | 1.73B |
| Net Income growth (YoY) | +65.85% | +5.14% | +112.60% | +13.64% | +91.96% | — | -18.25% | +63.58% | -45.90% | -103.98% | -52.54% | -19.27% |
| EPS (Basic) | 4.40 | 3.37 | 2.47 | 5.98 | 2.66 | 3.22 | 1.17 | 5.27 | 1.39 | -0.21 | 1.43 | 3.23 |
| EPS (Diluted) | 4.37 | 3.34 | 2.45 | 5.93 | 2.65 | 3.20 | 1.17 | 5.22 | 1.38 | -0.21 | 1.42 | 3.22 |
| Shares Outstanding (Basic) | 540.00M | 540.00M | — | 538.00M | 538.00M | 538.00M | — | 537.00M | 537.00M | 536.00M | — | 535.00M |
| Shares Outstanding (Diluted) | 544.00M | 544.00M | — | 542.00M | 541.00M | 541.00M | — | 542.00M | 541.00M | 536.00M | — | 538.00M |
| EBITDA | 4.63B | 3.78B | 3.85B | 3.83B | 4.00B | 2.56B | 3.71B | 3.44B | 3.31B | 2.39B | 2.65B | 2.92B |
| Gross Margin | 72.04% | 68.16% | 69.84% | 67.75% | 67.20% | 63.58% | 65.75% | 61.07% | 61.42% | 57.03% | 62.03% | 73.84% |
| Operating Margin | 34.95% | 30.94% | 27.57% | 26.43% | 28.94% | 14.46% | 25.43% | 24.07% | 22.76% | 13.31% | 15.51% | 29.28% |
| Net Margin | 23.62% | 21.11% | 13.51% | 33.65% | 15.60% | 21.23% | 6.90% | 33.28% | 8.89% | -1.52% | 9.36% | 25.06% |
This table shows 12 quarterly periods of Amgen's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AMGN's reporting calendar. What is a income statement?